European Journal of Dermatology

, Volume 28, Issue 3, pp 287–313 | Cite as

Application of electrochemotherapy in the management of primary and metastatic cutaneous malignant tumours: a systematic review and meta-analysis

  • S. Morteza Seyed JafariEmail author
  • Fatemeh Jabbary Lak
  • Amiq Gazdhar
  • Maziar Shafighi
  • Luca Borradori
  • Robert E. Hunger


Electrochemotherapy is becoming a promising technique for the management of malignancies of skin and non-skin origin. The current review aims to clarify current knowledge on administration of electrochemotherapy for the treatment of various skin tumours. A systematic literature search was performed, up to the end of 2016, on studies in which the application of electrochemotherapy for management of primary and metastatic cutaneous malignant tumours was assessed. Having selected appropriate studies, pooled estimates of mean objective (complete) responses, with 95% confidence intervals (CIs), were calculated to assess treatment efficacy. Finally, the main emerging themes from the papers were discussed in more detail. From 465 records identified through database searching, a total of 128 studies were screened, of which 70 were included for review. After a pooled analysis, the estimate for mean objective response following electrochemotherapy was 84.02% (95% CI: 80.08-87.61). Furthermore, the pooled estimate of objective treatment response of evaluated studies was 83.91% (95% CI: 79.15-88.17%) for bleomycin and 80.82% (95% CI: 66.00-92.36%) for cisplatin. Electrochemotherapy is a feasible, inexpensive, fast and easy technique to perform local treatment, regardless of tumour type, with a low level of adverse effects and patient discomfort. This method can be applied alone for patients with primary cutaneous lesions, or local or locoregional metastases, or as an additional treatment modality in patients with distant metastases.

Key words

clinical trials cutaneous malignant tumour electrochemotherapy metastasis 


  1. 1.
    Leiter U, Eigentler T, Garbe C. Epidemiology of skin cancer. Adv Exp Med Biol 2014; 810: 120–40.PubMedGoogle Scholar
  2. 2.
    Rodriguez–Cuevas S, Barroso–Bravo S, Almanza–Estrada J, Cristobal–Martinez L, Gonzalez–Rodriguez E. Electrochemotherapy in primary and metastatic skin tumors:phase II trial using intralesional bleomycin. Arch Med Res 2001; 32: 273–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Hunger RE, Angermeier S, Seyed Jafari SM, Ochsenbein A, Shafighi M. A retrospective study of 1–versus 2–cm excision margins for cutaneous malignant melanomas thicker than 2 mm. J Am Acad Dermatol 2015; 72: 1054–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Matthiessen LW, Chalmers RL, Sainsbury DC, et al. Management of cutaneous metastases using electrochemotherapy. Acta Oncol 2011; 50: 621–9.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Campana LG, Valpione S, Mocellin S, et al. Electrochemotherapy for disseminated superficial metastases from malignant melanoma. Br J Surg 2012; 99: 821–30.PubMedCrossRefGoogle Scholar
  6. 6.
    Okino M, Mohri H. Effects of a high–voltage electrical impulse and an anticancer drug on in vivo growing tumors. Jpn J Cancer Res 1987; 78: 1319–21.PubMedGoogle Scholar
  7. 7.
    Orlowski S, Belehradek J, Paoletti C, Mir LM. Transient electropermeabilization of cells in culture:increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol 1988; 37: 4727–33.PubMedCrossRefGoogle Scholar
  8. 8.
    Mir LM, Banoun H, Paoletti C. Introduction of definite amounts of nonpermeant molecules into living cells after electropermeabilization:direct access to the cytosol. Exp Cell Res 1988; 175: 15–25.PubMedCrossRefGoogle Scholar
  9. 9.
    Seyed Jafari SM, Shafighi M, Beltraminelli H, Geiser T, Hunger RE, Gazdhar A. Improvement of flap necrosis in a rat random skin flap model by in vivo electroporation–mediated HGF gene transfer. Plast Reconstr Surg 2017; 139: 1116e–27e.CrossRefGoogle Scholar
  10. 10.
    Seyed Jafari SM, Shafighi M, Beltraminelli H, et al. Efficacy of in vivo electroporation–mediated IL–10 gene delivery on survival of skin flaps. J Membr Biol 2018; 251: 211–219.PubMedCrossRefGoogle Scholar
  11. 11.
    Quaglino P, Mortera C, Osella–Abate S, et al. Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol 2008; 15: 2215–22.PubMedCrossRefGoogle Scholar
  12. 12.
    Gehl J, Geertsen PF. Efficient palliation of haemorrhaging malignant melanoma skin metastases by electrochemotherapy. Melanoma Res 2000; 10: 585–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Rols MP, Bachaud JM, Giraud P, Chevreau C, Roche H, Teissie J. Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res 2000; 10: 468–74.PubMedCrossRefGoogle Scholar
  14. 14.
    Gothelf A, Mir LM, Gehl J. Electrochemotherapy:results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 2003; 29: 371–87.PubMedCrossRefGoogle Scholar
  15. 15.
    Marty M, Sersa G, Garbay JR, et al. Electrochemotherapy–An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases:results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. EJC Suppl 2006; 4: 3–13.CrossRefGoogle Scholar
  16. 16.
    Plaschke CC, Gothelf A, Gehl J, Wessel I. Electrochemotherapy of mucosal head and neck tumors:a systematic review. Acta Oncol 2016; 55: 1266–72.PubMedCrossRefGoogle Scholar
  17. 17.
    Sersa G, Stabuc B, Cemazar M, Miklavcic D, Rudolf Z. Electrochemotherapy with cisplatin:clinical experience in malignant melanoma patients. Clin Cancer Res 2000; 6: 863–7.PubMedGoogle Scholar
  18. 18.
    Mir L, Orlowski S, Belehradek J, et al. Biomedical applications of electric pulses with special emphasis on antitumor electrochemotherapy. Bioelectrochem Bioenerg 1995; 38: 203–7.CrossRefGoogle Scholar
  19. 19.
    Rols M–P, Teissie J. Electropermeabilization of mammalian cells. Quantitative analysis of the phenomenon. Biophys J 1990; 58: 1089.PubMedGoogle Scholar
  20. 20.
    Sersa G, Stabuc B, Cemazar M, Miklavcic D, Rudolf Z. Electrochemotherapy with cisplatin:the systemic antitumor effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases. Melanoma Res 2000; 10: 381–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Mir LM, Glass LF, Sersa G, et al. Effective treatment of cutaneous and subcutaneous malignant tumors by electrochemotherapy. Br J Cancer 1998; 77: 2336–42.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Heller R, Gilbert R, Jaroszeski MJ. Clinical applications of electrochemotherapy. Adv Drug Deliv Rev 1999; 35: 119–29.PubMedCrossRefGoogle Scholar
  23. 23.
    Kaehler KC, Egberts F, Hauschild A. Electrochemotherapy in symptomatic melanoma skin metastases:intraindividual comparison with conventional surgery. Dermatol Surg 2010; 36: 1200–2.PubMedCrossRefGoogle Scholar
  24. 24.
    Sersa G, Cemazar M, Miklavcic D. Antitumor effectiveness of electrochemotherapy with cis–diamminedichloroplatinum(II) in mice. Cancer Res 1995; 55: 3450–5.PubMedGoogle Scholar
  25. 25.
    Heller R, Jaroszeski M, Perrott R, Messina J, Gilbert R. Effective treatment of B16 melanoma by direct delivery of bleomycin using electrochemotherapy. Melanoma Res 1997; 7: 10–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Cemazar M, Milacic R, Miklavcic D, Dolzan V, Sersa G. Intratumoral cisplatin administration in electrochemotherapy:antitumor effectiveness, sequence dependence and platinum content. Anticancer Drugs 1998; 9: 525–30.PubMedCrossRefGoogle Scholar
  27. 27.
    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta–analyses:the PRISMA statement. Ann Intern Med 2009; 151: 264–9.PubMedCrossRefGoogle Scholar
  28. 28.
    DerSimonian R, Laird N. Meta–analysis in clinical trials. Control Clin Trials 1986; 7: 177–88.PubMedCrossRefGoogle Scholar
  29. 29.
    Queirolo P, Marincola F, Spagnolo F. Electrochemotherapy for the management of melanoma skin metastasis:a review of the literature and possible combinations with immunotherapy. Arch Dermatol Res 2014; 306: 521–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Rudolf Z, Stabuc B, Cemazar M, Miklavcic D, Vodovnik L, Sersa G. Electrochemotherapy with bleomycin. The first clinical experience in malignant melanoma patients. Radiol Oncol 1995; 29: 229–35.Google Scholar
  31. 31.
    Tounekti O, Pron G, Belehradek J Jr., Mir LM. Bleomycin, an apoptosis–mimetic drug that induces two types of cell death depending on the number of molecules internalized. Cancer Res 1993; 53: 5462–9.PubMedGoogle Scholar
  32. 32.
    Pron G, Belehradek J, Mir L. Identification of a plasma membrane protein that specifically binds bleomycin. Biochem Biophys Res Commun 1993; 194: 333–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Pron G, Belehradek J, Orlowski S, Mir LM. Involvement of membrane bleomycin–binding sites in bleomycin cytotoxicity. Biochem Pharmacol 1994; 48: 301–10.PubMedCrossRefGoogle Scholar
  34. 34.
    Poddevin B, Orlowski S, Belehradek J, Mir L. Very high cytotoxicity of bleomycin introduced into the cytosol of cells in culture. Biochem Pharmacol 1991;42:S67–75.PubMedCrossRefGoogle Scholar
  35. 35.
    Belehradek J Jr., Orlowski S, Ramirez LH, Pron G, Poddevin B, Mir LM. Electropermeabilization of cells in tissues assessed by the qualitative and quantitative electroloading of bleomycin. Biochim Biophys Acta 1994; 1190: 155–63.PubMedCrossRefGoogle Scholar
  36. 36.
    Gehl J, Geertsen PF. Palliation of haemorrhaging and ulcerated cutaneous tumors using electrochemotherapy. EJC Suppl 2006; 4: 35–7.CrossRefGoogle Scholar
  37. 37.
    Kis E, Olah J, Ocsai H, et al. Electrochemotherapy of cutaneous metastases of melanoma–a case series study and systematic review of the evidence. Dermatol Surg 2011; 37: 816–24.PubMedGoogle Scholar
  38. 38.
    Glass LF, Fenske NA, Jaroszeski M, et al. Bleomycin–mediated electrochemotherapy of basal cell carcinoma. J Am Acad Dermatol 1996; 34: 82–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Heller R, Jaroszeski MJ, Glass LF, et al. Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer 1996; 77: 964–71.PubMedCrossRefGoogle Scholar
  40. 40.
    Ricotti F, Giuliodori K, Cataldi I, et al. Electrochemotherapy:an effective local treatment of cutaneous and subcutaneous melanoma metastases. Dermatol Ther 2014; 27: 148–52.PubMedCrossRefGoogle Scholar
  41. 41.
    Solari N, Spagnolo F, Ponte E, et al. Electrochemotherapy for the management of cutaneous and subcutaneous metastasis:a series of 39 patients treated with palliative intent. J Surg Oncol 2014; 109: 270–4.PubMedCrossRefGoogle Scholar
  42. 42.
    Heller R, Jaroszeski MJ, Reintgen DS, et al. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 1998; 83: 148–57.PubMedCrossRefGoogle Scholar
  43. 43.
    Skarlatos I, Kyrgias G, Mosa E, et al. Electrochemotherapy in cancer patients:first clinical trial in Greece. In Vivo 2011; 25: 265–74.PubMedGoogle Scholar
  44. 44.
    Bertino G, Sersa G, De Terlizzi F, et al. European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project:results of the treatment of skin cancer. Eur J Cancer 2016; 63: 41–52.PubMedCrossRefGoogle Scholar
  45. 45.
    Valpione S, Campana LG, Pigozzo J, Chiarion–Sileni V. Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib. Radiol Oncol 2015; 49: 71–4.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Caraco C, Mozzillo N, Marone U, et al. Long–lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis. BMC Cancer 2013; 13: 564.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Kreuter A, van Eijk T, Lehmann P, et al. Electrochemotherapy in advanced skin tumors and cutaneous metastases–a retrospective multicenter analysis. J Dtsch Dermatol Ges 2015; 13: 308–15.PubMedGoogle Scholar
  48. 48.
    Hribernik A, Cemazar M, Sersa G, Bosnjak M, Snoj M. Effectiveness of electrochemotherapy after IFN–alpha adjuvant therapy of melanoma patients. Radiol Oncol 2016; 50: 21–7.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Campana LG, Testori A, Curatolo P, et al. Treatment efficacy with electrochemotherapy:a multi–institutional prospective observational study on 376 patients with superficial tumors. Eur J Surg Oncol 2016; 42: 1914–23.PubMedCrossRefGoogle Scholar
  50. 50.
    Fantini F, Gualdi G, Cimitan A, Giannetti A. Metastatic basal cell carcinoma with squamous differentiation:report of a case with response of cutaneous metastases to electrochemotherapy. Arch Dermatol 2008; 144: 1186–8.PubMedGoogle Scholar
  51. 51.
    Salwa SP, Bourke MG, Forde PF, et al. Electrochemotherapy for the treatment of ocular basal cell carcinoma;a novel adjunct in the disease management. J Plast Reconstr Aesthet Surg 2014; 67: 403–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Kis E, Baltas E, Kinyo A, et al. Successful treatment of multiple basaliomas with bleomycin–based electrochemotherapy:a case series of three patients with Gorlin–Goltz syndrome. Acta Derm Venereol 2012; 92: 648–51.PubMedCrossRefGoogle Scholar
  53. 53.
    Macri GF, Greco A, Gallo A, Fusconi M, Marinelli C, de Vincentiis M. Use of electrochemotherapy in a case of neck skin metastasis of oral squamous cell carcinoma:case report and considerations. Head Neck 2014; 36:e86–90.Google Scholar
  54. 54.
    Gualdi G, Monari P, Fantini F, Cesinaro AM, Cimitan A. Electrochemotherapy–induced virus disappearance in HHV–8–positive skin nodules of Kaposi sarcoma:first histological and immunohistochemical demonstration of efficacy. J Eur Acad Dermatol Venereol 2010; 24: 239–41.PubMedCrossRefGoogle Scholar
  55. 55.
    Curatolo P, Quaglino P, Marenco F, et al. Electrochemotherapy in the treatment of Kaposi sarcoma cutaneous lesions:a two–center prospective phase II trial. Ann Surg Oncol 2012; 19: 192–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Garbay J–R, Billard V, Bernat C, Mir LM, Morsli N, Robert C. Successful repetitive treatments by electrochemotherapy of multiple unresectable Kaposi sarcoma nodules. EJC Suppl 2006; 4: 29–31.CrossRefGoogle Scholar
  57. 57.
    Curatolo P, Mancini M, Ruggiero A, Clerico R, Di Marco P, Calvieri S. Successful treatment of penile Kaposi’s sarcoma with electrochemotherapy. Dermatol Surg 2008; 34: 839–42, discussion:42–3.PubMedGoogle Scholar
  58. 58.
    Di Monta G, Caraco C, Benedetto L, et al. Electrochemotherapy as “new standard of care” treatment for cutaneous Kaposi’s sarcoma. Eur J Surg Oncol 2014; 40: 61–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Latini A, Bonadies A, Trento E, et al. Effective treatment of Kaposi’s sarcoma by electrochemotherapy and intravenous bleomycin administration. Dermatol Ther 2012; 25: 214–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Curatolo P, Mancini M, Clerico R, et al. Remission of extensive Merkel cell carcinoma after electrochemotherapy. Arch Dermatol 2009; 145: 494–5.PubMedCrossRefGoogle Scholar
  61. 61.
    Scelsi D, Mevio N, Bertino G, et al. Electrochemotherapy as a new therapeutic strategy in advanced Merkel cell carcinoma of head and neck region. Radiol Oncol 2013; 47: 366–9.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Larkin JO, Collins CG, Aarons S, et al. Electrochemotherapy:aspects of preclinical development and early clinical experience. Ann Surg 2007; 245: 469–79.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Bourke MG, Salwa SP, Sadadcharam M, et al. Effective treatment of intractable cutaneous metastases of breast cancer with electrochemotherapy:ten–year audit of single centre experience. Breast Cancer Res Treat 2017; 161: 289–97.PubMedCrossRefGoogle Scholar
  64. 64.
    Whelan MC, Larkin JO, Collins CG, et al. Effective treatment of an extensive recurrent breast cancer which was refractory to multimodal therapy by multiple applications of electrochemotherapy. EJC Suppl 2006; 4: 32–4.CrossRefGoogle Scholar
  65. 65.
    Campana LG, Valpione S, Falci C, et al. The activity and safety of electrochemotherapy in persistent chest wall recurrence from breast cancer after mastectomy:a phase–II study. Breast Cancer Res Treat 2012; 134: 1169–78.PubMedCrossRefGoogle Scholar
  66. 66.
    Matthiessen LW, Johannesen HH, Hendel HW, Moss T, Kamby C, Gehl J. Electrochemotherapy for large cutaneous recurrence of breast cancer:a phase II clinical trial. Acta Oncol 2012; 51: 713–21.PubMedCrossRefGoogle Scholar
  67. 67.
    Benevento R, Santoriello A, Perna G, Canonico S. Electrochemotherapy of cutaneous metastastes from breast cancer in elderly patients:a preliminary report. BMC Surg 2012;12:S6.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Cabula C, Campana LG, Grilz G, et al. Electrochemotherapy in the treatment of cutaneous metastases from breast cancer:a multicenter cohort analysis. Ann Surg Oncol 2015;22:S442–50.PubMedCrossRefGoogle Scholar
  69. 69.
    Campana LG, Bianchi G, Mocellin S, et al. Electrochemotherapy treatment of locally advanced and metastatic soft tissue sarcomas:results of a non–comparative phase II study. World J Surg 2014; 38: 813–22.PubMedCrossRefGoogle Scholar
  70. 70.
    Gatti A, Stinco G, Trevisini S, et al. Electrochemotherapy as a novel treatment for primary cutaneous marginal zone B–cell lymphomas. Dermatol Ther 2014; 27: 244–7.PubMedCrossRefGoogle Scholar
  71. 71.
    Guida M, Campana LG, Curatolo P, et al. Local treatment with electrochemotherapy of superficial angiosarcomas:efficacy and safety results from a multi–institutional retrospective study. J Surg Oncol 2016; 114: 246–53.PubMedCrossRefGoogle Scholar
  72. 72.
    Kubota Y, Mir LM, Nakada T, Sasagawa I, Suzuki H, Aoyama N. Successful treatment of metastatic skin lesions with electrochemotherapy. J Urol 1998; 160: 1426.PubMedCrossRefGoogle Scholar
  73. 73.
    Snoj M, Cemazar M, Srnovrsnik T, Kosir SP, Sersa G. Limb sparing treatment of bleeding melanoma recurrence by electrochemotherapy. Tumori 2009; 95: 398–402.PubMedCrossRefGoogle Scholar
  74. 74.
    Kubota Y, Tomita Y, Tsukigi M, Kurachi H, Motoyama T, Mir LM. A case of perineal malignant melanoma successfully treated with electrochemotherapy. Melanoma Res 2005; 15: 133–4.PubMedCrossRefGoogle Scholar
  75. 75.
    Lido P, Paolino G, Feliziani A, et al. Cutaneous metastasis of unknown primary presenting as massive and invasive abdominal lesion:an elective approach with electrochemotherapy. An Bras Dermatol 2015; 90: 879–82.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Escoffre JM, Rols MP. Electrochemotherapy:progress and prospects. Curr Pharm Des 2012; 18: 3406–15.PubMedCrossRefGoogle Scholar
  77. 77.
    Cemazar M, Miklavcic D, Vodovnik L, et al. Improved therapeutic effect of electrochemotherapy with cisplatin by intratumoral drug administration and changing of electrode orientation for electropermeabilization on EAT tumor model in mice. Radiol Oncol 1995; 29: 121–7.Google Scholar
  78. 78.
    Sersa G, Stabuc B, Cemazar M, Jancar B, Miklavcic D, Rudolf Z. Electrochemotherapy with cisplatin:potentiation of local cisplatin antitumour effectiveness by application of electric pulses in cancer patients. Eur J Cancer 1998; 34: 1213–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Snoj M, Rudolf Z, Cemazar M, Jancar B, Sersa G. Successful sphincter–saving treatment of anorectal malignant melanoma with electrochemotherapy, local excision and adjuvant brachytherapy. Anticancer Drugs 2005; 16: 345–8.PubMedCrossRefGoogle Scholar
  80. 80.
    Rebersek M, Cufer T, Cemazar M, Kranjc S, Sersa G. Electrochemotherapy with cisplatin of cutaneous tumor lesions in breast cancer. Anticancer Drugs 2004; 15: 593–7.PubMedCrossRefGoogle Scholar
  81. 81.
    Mir LM, Gehl J, Sersa G, et al. Standard operating procedures of the electrochemotherapy:instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the Cliniporator TM by means of invasive or non–invasive electrodes. EJC Suppl 2006; 4: 14–25.CrossRefGoogle Scholar
  82. 82.
    Testori A, Tosti G, Martinoli C, et al. Electrochemotherapy for cutaneous and subcutaneous tumor lesions:a novel therapeutic approach. Dermatol Ther 2010; 23: 651–61.PubMedCrossRefGoogle Scholar
  83. 83.
    Mir LM. Therapeutic perspectives of in vivo cell electropermeabilization. Bioelectrochemistry 2001; 53: 1–10.PubMedCrossRefGoogle Scholar
  84. 84.
    Miklavčič D, Serša G, Brecelj E, et al. Electrochemotherapy:technological advancements for efficient electroporation–based treatment of internal tumors. Med Biol Eng Comput 2012; 50: 1213–25.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Domenge C, Orlowski S, Luboinski B, et al. Antitumor electrochemotherapy:new advances in the clinical protocol. Cancer 1996; 77: 956–63.PubMedCrossRefGoogle Scholar
  86. 86.
    Miklavcic D, Corovic S, Pucihar G, Pavselj N. Importance of tumour coverage by sufficiently high local electric field for effective electrochemotherapy. EJC Suppl 2006; 4: 45–51.CrossRefGoogle Scholar
  87. 87.
    Gehl J, Sorensen TH, Nielsen K, et al. In vivo electroporation of skeletal muscle:threshold, efficacy and relation to electric field distribution. Biochim Biophys Acta 1999; 1428: 233–40.PubMedCrossRefGoogle Scholar
  88. 88.
    Ramirez LH, Orlowski S, An D, et al. Electrochemotherapy on liver tumours in rabbits. Br J Cancer 1998; 77: 2104–11.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Snoj M, Cemazar M, Kolar BS, Sersa G. Effective treatment of multiple unresectable skin melanoma metastases by electrochemotherapy. Croat Med 2007; 48: 391.Google Scholar
  90. 90.
    Campana LG, Testori A, Mozzillo N, Rossi CR. Treatment of metastatic melanoma with electrochemotherapy. J Surg Oncol 2014; 109: 301–7.PubMedCrossRefGoogle Scholar
  91. 91.
    Miklavcic D, Pucihar G, Pavlovec M, et al. The effect of high frequency electric pulses on muscle contractions and antitumor efficiency in vivo for a potential use in clinical electrochemotherapy. Bioelectrochemistry 2005; 65: 121–8.PubMedCrossRefGoogle Scholar
  92. 92.
    Sersa G, Cemazar M, Rudolf Z. Electrochemotherapy:advantages and drawbacks in treatment of cancer patients. Cancer Ther 2003; 1: 133–42.Google Scholar
  93. 93.
    Glass LF, Jaroszeski M, Gilbert R, Reintgen DS, Heller R. Intralesional bleomycin–mediated electrochemotherapy in 20 patients with basal cell carcinoma. J Am Acad Dermatol 1997; 37: 596–9.PubMedCrossRefGoogle Scholar
  94. 94.
    Byrne CM, Thompson JF, Johnston H, et al. Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanom Res 2005; 15: 45–51.CrossRefGoogle Scholar
  95. 95.
    Gaudy C, Richard MA, Folchetti G, Bonerandi JJ, Grob JJ. Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma. J Cutan Med Surg 2006; 10: 115–21.PubMedCrossRefGoogle Scholar
  96. 96.
    Tijink BM, De Bree R, Van Dongen GA, Leemans CR. How we do it:chemo–electroporation in the head and neck for otherwise untreatable patients. Clin Otolaryngol 2006; 31: 447–51.PubMedCrossRefGoogle Scholar
  97. 97.
    Glass LF, Pepine ML, Fenske NA, Jaroszeski M, Reintgen DS, Heller R. Bleomycin–mediated electrochemotherapy of metastatic melanoma. Arch Dermatol 1996; 132: 1353–7.PubMedCrossRefGoogle Scholar
  98. 98.
    Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek J Jr., Mir LM. Electrochemotherapy, a new antitumor treatment. First clinical phase I–II trial. Cancer 1993; 72: 3694–700.PubMedGoogle Scholar
  99. 99.
    Landstrom FJ, Nilsson CO, Crafoord S, Reizenstein JA, Adamsson GB, Lofgren LA. Electroporation therapy of skin cancer in the head and neck area. Dermatol Surg 2010; 36: 1245–50.PubMedCrossRefGoogle Scholar
  100. 100.
    Marenco F, Nardo T, Savoia P, Bernengo MG. Effectiveness of electrochemotherapy in treatment of a recurrent squamous cell carcinoma of the scalp. Eur J Dermatol 2011; 21: 618–9.PubMedGoogle Scholar
  101. 101.
    Quaglino P, Matthiessen LW, Curatolo P, et al. Predicting patients at risk for pain associated with electrochemotherapy. Acta Oncol 2015; 54: 298–306.PubMedCrossRefGoogle Scholar
  102. 102.
    Campana LG, Mocellin S, Basso M, et al. Bleomycin–based electrochemotherapy:clinical outcome from a single institution’s experience with 52 patients. Ann Surgical Oncol 2009; 16: 191–9.CrossRefGoogle Scholar
  103. 103.
    Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma:state of the art 2006. Melanoma Res 2007; 17: 117–27.PubMedCrossRefGoogle Scholar
  104. 104.
    Jarm T, Cemazar M, Miklavcic D, Sersa G. Antivascular effects of electrochemotherapy:implications in treatment of bleeding metastases. Expert Rev Anticancer Ther 2010; 10: 729–46.PubMedCrossRefGoogle Scholar
  105. 105.
    Sersa G, Cemazar M, Snoj M. Electrochemotherapy of tumours. Curr Oncol 2009; 16: 34–5.PubMedPubMedCentralGoogle Scholar
  106. 106.
    Sersa G, Cemazar M, Parkins CS, Chaplin DJ. Tumor blood flow changes induced by application of electric pulses. Eur J Cancer 1999; 35: 672–7.PubMedCrossRefGoogle Scholar
  107. 107.
    Mali B, Jarm T, Snoj M, Sersa G, Miklavcic D. Antitumor effectiveness of electrochemotherapy:a systematic review and metaanalysis. Eur J Surg Oncol 2013; 39: 4–16.PubMedCrossRefGoogle Scholar
  108. 108.
    Mir–Bonafe JM, Vilalta A, Alarcon I, et al. Electrochemotherapy in the treatment of melanoma skin metastases:a report on 31 cases. Actas Dermosifiliogr 2015; 106: 285–91.PubMedCrossRefGoogle Scholar
  109. 109.
    Allegretti JP, Panje WR. Electroporation therapy for head and neck cancer including carotid artery involvement. Laryngoscope 2001; 111: 52–6.PubMedCrossRefGoogle Scholar
  110. 110.
    Sersa G. The state–of–the–art of electrochemotherapy before the ESOPE study;advantages and clinical uses. EJC Suppl 2006; 4: 52–9.CrossRefGoogle Scholar
  111. 111.
    Gilbert RA, Jaroszeski MJ, Heller R. Novel electrode designs for electrochemotherapy. Biochim Biophys Acta 1997; 1334: 9–14.PubMedCrossRefGoogle Scholar
  112. 112.
    Testori A, Faries MB, Thompson JF, et al. Local and intralesional therapy of in–transit melanoma metastases. J Surg Oncol 2011; 104: 391–6.PubMedCrossRefGoogle Scholar
  113. 113.
    Byrne CM, Thompson JF. Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors. Expert Rev Anticancer Ther 2006; 6: 671–8.PubMedCrossRefGoogle Scholar
  114. 114.
    Kunte C, Letule V, Gehl J, et al. Electrochemotherapy in the treatment of metastatic malignant melanoma:a prospective cohort study by InspECT. Br J Dermatol 2017; 176: 1475–85.PubMedCrossRefGoogle Scholar
  115. 115.
    Mir LM, Orlowski S, Poddevin B, Belehradek J Jr. Electrochemotherapy tumor treatment is improved by interleukin–2 stimulation of the host’s defenses. Eur Cytokine Netw 1992; 3: 331–4.PubMedGoogle Scholar
  116. 116.
    Mir LM, Roth C, Orlowski S, et al. Potentiation of the antitumoral effect of electrochemotherapy by immunotherapy with allogeneic cells producing interleukin 2. C R Acad Sci III 1992; 314: 539–44.PubMedGoogle Scholar
  117. 117.
    Mir LM, Roth C, Orlowski S, et al. Systemic antitumor effects of electrochemotherapy combined with histoincompatible cells secreting interleukin–2. J Immunother Emphasis Tumor Immunol 1995; 17: 30–8.PubMedCrossRefGoogle Scholar
  118. 118.
    Spanggaard I, Gehl J. Antiangiogenic metargidin peptide (AMEP) gene therapy in disseminated melanoma. Methods Mol Biol 2015; 1317: 359–64.PubMedCrossRefGoogle Scholar
  119. 119.
    Daud AI, DeConti RC, Andrews S, et al. Phase I trial of interleukin–12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26: 5896–903.PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Mir LM. Electroporation–based gene therapy:recent evolution in the mechanism description and technology developments. Methods Mol Biol 2014; 1121: 3–23.PubMedCrossRefGoogle Scholar
  121. 121.
    Gehl J. Gene electrotransfer in clinical trials. Methods Mol Biol 2014; 1121: 241–6.PubMedCrossRefGoogle Scholar
  122. 122.
    Testori A, Rossi CR, Tosti G. Utility of electrochemotherapy in melanoma treatment. Curr Opin Oncol 2012; 24: 155–61.PubMedCrossRefGoogle Scholar
  123. 123.
    Mozzillo N, Simeone E, Benedetto L, et al. Assessing a novel immuno–oncology–based combination therapy:ipilimumab plus electrochemotherapy. Oncoimmunology 2015; 4:e1008842.CrossRefGoogle Scholar

Copyright information

© John Libbey Eurotext 2018

Authors and Affiliations

  • S. Morteza Seyed Jafari
    • 1
    • 2
    • 3
    Email author
  • Fatemeh Jabbary Lak
    • 4
  • Amiq Gazdhar
    • 2
    • 5
  • Maziar Shafighi
    • 2
  • Luca Borradori
    • 1
  • Robert E. Hunger
    • 1
    • 2
  1. 1.Department of Dermatology, InselspitalBern University HospitalBernSwitzerland
  2. 2.Department for BioMedical ResearchUniversity of BernBernSwitzerland
  3. 3.Graduate School for Cellular and Biomedical SciencesUniversity of BernBernSwitzerland
  4. 4.Münsingen HospitalMünsingenSwitzerland
  5. 5.Department of Pulmonary MedicineBern University HospitalBernSwitzerland

Personalised recommendations